A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Inclusion Criteria:

- Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and
without early termination of study drug.

- Are willing and able to complete the scheduled study assessments, including endoscopy
and daily diary entry.

- If female, must meet the contraception requirements.

Exclusion Criteria:

- Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified
(indeterminate colitis) during the induction study AMAN (NCT03518086).

- Participants with a bowel resection or other surgery for the treatment of UC during
the previous induction study AMAN (NCT03518086), or are likely to require surgery for
the treatment of UC during study AMBG.

- Participants with evidence of colonic dysplasia or have been diagnosed with cancer of
the gastrointestinal tract during study AMAN (NCT03518086).

- Participants diagnosed with clinically important infection including, but not limited
to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during the
induction study AMAN (NCT03518086).

- Participants who initiate a new prohibited medication during the induction study AMAN
(NCT03518086).

- Participants with certain laboratory abnormalities prior to start of AMBG that would
require permanent discontinuation from study drug.